State Street Corp Surface Oncology, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.42 - $3.15 $587,644 - $1.3 Million	-413,834 Reduced 70.69%	171,566 $281,000
Q1 2022 May 16, 2022	BUY	$2.65 - $5.08 $25,177 - $48,265	9,501 Added 1.65%	585,400 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $343,710 - $574,061	72,666 Added 14.44%	575,899 $2.75 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $7.98 $345,229 - $533,901	66,905 Added 15.33%	503,233 $3.81 Million
Q2 2021 Aug 16, 2021	BUY	$6.45 - $9.09 $2.7 Million - $3.8 Million	418,328 Added 2324.04%	436,328 $3.26 Million
Q1 2021 May 17, 2021	BUY	$7.25 - $13.82 $10,150 - $19,348	1,400 Added 8.43%	18,000 $140,000
Q3 2020 Nov 10, 2020	BUY	$5.06 - $7.23 $83,996 - $120,018	16,600 New	16,600 $115,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.